W-T7 Shows Encouraging Response Rate, Manageable ...
Ibrahim Aldoss presented phase 2 results of the WU-CART-007 trial at EHA 2024, showing a 91% overall response rate and manageable safety profile for W-T7, a CD7-targeted CAR T-cell therapy in relapsed/refractory T-ALL/LBL patients. A registration study is planned to further evaluate efficacy.
Reference News
W-T7 Shows Encouraging Response Rate, Manageable ...
Ibrahim Aldoss presented phase 2 results of the WU-CART-007 trial at EHA 2024, showing a 91% overall response rate and manageable safety profile for W-T7, a CD7-targeted CAR T-cell therapy in relapsed/refractory T-ALL/LBL patients. A registration study is planned to further evaluate efficacy.